Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Phase 2
Not yet recruiting
- Conditions
- Multiple Myeloma, Newly DiagnosedMultiple Myeloma (MM)
- Interventions
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 100
- Registration Number
- NCT06974786
Lenalidomide vs Methotrexate in Difficult-to-treat Cutaneous Lupus Erythematosus
Phase 3
Not yet recruiting
- Conditions
- Cutaneous Lupus Erythematosus (CLE)
- Interventions
- First Posted Date
- 2025-05-11
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 122
- Registration Number
- NCT06965244
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
Phase 3
Not yet recruiting
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2025-04-17
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- European Myeloma Network B.V.
- Target Recruit Count
- 1000
- Registration Number
- NCT06932562
Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)
Phase 2
Not yet recruiting
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2025-04-17
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 176
- Registration Number
- NCT06931704
- Locations
- 🇫🇷
CHU Angers, Angers, France
🇫🇷CH Côte Basque, Bayonne, France
🇫🇷CHU Besançon, Besançon, France
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
Phase 3
Not yet recruiting
- Conditions
- Multiple Myeloma, Newly Diagnosed
- Interventions
- Drug: Daratumumab SC (Darzalex)Procedure: Autologous Stem Cell Transplantation
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Intergroupe Francophone du Myelome
- Target Recruit Count
- 824
- Registration Number
- NCT06918002
Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse
Phase 2
Not yet recruiting
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Dickran Kazandjian, MD
- Target Recruit Count
- 32
- Registration Number
- NCT06910124
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma (GOLSEEK-4)
Phase 3
Not yet recruiting
- Conditions
- Follicular Lymphoma
- Interventions
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Celgene
- Target Recruit Count
- 400
- Registration Number
- NCT06911502
- Locations
- 🇺🇸
Local Institution - 0214, Tampa, Florida, United States
🇵🇱Local Institution - 0189, Łódź, Łódzkie, Poland
🇺🇸Local Institution - 0008, Jacksonville, Florida, United States
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
Phase 1
Not yet recruiting
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 440
- Registration Number
- NCT06892522
SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial
Phase 2
Recruiting
- Conditions
- Solitary Plasmacytoma
- Interventions
- Radiation: SBRT
- First Posted Date
- 2025-03-07
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 41
- Registration Number
- NCT06863584
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Hangzhou, Zhejiang, China
Efficacy and Safety of Pola-RCHP-X Vs Pola-RCHP in Untreated DLBCL
Phase 2
Not yet recruiting
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2025-01-31
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 152
- Registration Number
- NCT06803693
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath